Weifeng Li
P.R. China
Huzhou, 313100, China
Huzhou, 313100, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Impact of sleep duration on bone mineral density and osteoporosis risk: A systematic review and meta-analysis.
Journal: Pakistan journal of medical sciences
Published: January 28, 2026
Arteannuin B, a novel NLRP3 inhibitor, suppresses NLRP3 inflammasome in macrophages and alleviates NLRP3-related diseases.
Journal: International immunopharmacology
Published: October 25, 2025
Modulating the NLRP3 Inflammasome: Acitretin as a potential treatment for Sepsis-induced acute lung injury.
Journal: International immunopharmacology
Published: January 27, 2025
Corrigendum to "Tanshinone IIA analogue 15a inhibits NLRP3-mediated inflammation by activating mitophagy in macrophages to alleviate acute tubular necrosis" [Int. Immunopharmacol. 118 (2023) 110065].
Journal: International immunopharmacology
Published: July 05, 2023
Ergolide covalently binds NLRP3 and inhibits NLRP3 inflammasome-mediated pyroptosis.
Journal: International immunopharmacology
Published: February 20, 2023
Tanshinone IIA analogue 15a inhibits NLRP3-mediated inflammation by activating mitophagy in macrophages to alleviate acute tubular necrosis.
Journal: International immunopharmacology
Published: January 28, 2023
Discovery of alantolactone as a naturally occurring NLRP3 inhibitor to alleviate NLRP3-driven inflammatory diseases in mice.
Journal: British journal of pharmacology
Published: September 21, 2022
Costunolide covalently targets NACHT domain of NLRP3 to inhibit inflammasome activation and alleviate NLRP3-driven inflammatory diseases.
Journal: Acta pharmaceutica Sinica. B
Published: May 10, 2022
Showing 1-8 of 8
Last Updated: 09/26/2026